United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Primary listing
Employees
1,305
Headquarters
Website
UTHR Metrics
BasicAdvanced
$19B
16.20
$25.63
0.66
-
Price and volume
Market cap
$19B
Beta
0.66
52-week high
$459.48
52-week low
$266.98
Average daily volume
747K
Financial strength
Current ratio
7.26
Quick ratio
6.504
Interest coverage (TTM)
48.32%
Profitability
EBITDA (TTM)
1,597.1
Gross margin (TTM)
88.98%
Net profit margin (TTM)
40.36%
Operating margin (TTM)
49.30%
Effective tax rate (TTM)
23.18%
Revenue per employee (TTM)
$2,360,000
Management effectiveness
Return on assets (TTM)
12.96%
Return on equity (TTM)
19.30%
Valuation
Price to earnings (TTM)
16.204
Price to revenue (TTM)
6.052
Price to book
2.62
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
17.393
Free cash flow yield (TTM)
5.75%
Free cash flow per share (TTM)
23.88
Growth
Revenue change (TTM)
17.62%
Earnings per share change (TTM)
17.94%
3-year revenue growth (CAGR)
19.83%
10-year revenue growth (CAGR)
8.58%
3-year earnings per share growth (CAGR)
24.75%
10-year earnings per share growth (CAGR)
22.87%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Bulls say / Bears say
United Therapeutics posted record Q2 2025 revenue of $799 million, up 12% year-over-year and marking its twelfth straight quarter of double-digit growth, demonstrating the strength of its main commercial portfolio (BioSpace).
The Board approved a $1 billion stock buyback program running through March 31, 2026, underscoring management's confidence in the company’s balance sheet and future ability to generate cash (BioSpace).
Enrollment wrapped for the Phase 3 ADVANCE OUTCOMES study of oral ralinepag and the Phase 3 TETON 2 trial of nebulized Tyvaso, with results expected in September 2025 and the first half of 2026, offering near-term clinical catalysts (BioSpace).
Q2 2025 EPS was $6.41, missing the Zacks Consensus Estimate of $6.80. Shares fell 5.3% on July 30, indicating investors were dissatisfied with execution (NASDAQ).
Remodulin sales dropped 9% year-over-year to $134.7 million, showing the effects of more generic competition and a patient shift toward easier administration methods (NASDAQ).
Selling, general and administrative expenses rose 20% to $212.5 million year-over-year due to higher personnel and legal costs, putting pressure on operating margins (NASDAQ).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
Business Wire2 weeks ago
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
Business Wire1 month ago
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $19B as of October 29, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 16.2 as of October 29, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.